

## DAFTAR PUSTAKA

1. Jiao H, Acar G, Robinson GA, Ciurtin C, Jury EC, Kalea AZ. Diet and Systemic Lupus Erythematosus (SLE): From Supplementation to Intervention. *Int J Environ Res Public Health*. 2022;19(19):1–22.
2. Molina Rios S, Rojas Martinez R, Estévez Ramirez GM, Medina YF. Systemic Lupus Erythematosus and Antiphospholipid Syndrome After COVID-19 Vaccination. A Case Report. *Mod Rheumatol case reports*. 2022 Mar;Maret 4(rxac018):1–15.
3. Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. *Ann Rheum Dis*. 2022;1(1):1–6.
4. Tsai HL, Chang JW, Lu JH, Liu CS. Epidemiology and risk factors associated with avascular necrosis in patients with autoimmune diseases: a nationwide study. *Korean J Intern Med*. 2022;37(4):864–76.
5. Taufik A, Wachjudi RG, Hamijoyo L. Factors Related to Infection in Systemic Lupus Erythematosus Patients Admitted to the Hospital. *Indones J Rheumatol*. 2022;14(1):588–97.
6. La Cava A. Chapter 9 - Overview of the pathogenesis of systemic lupus erythematosus. In: Tsokos GCBTSLE (Second E, editor. *Systemic Lupus Erythematosus (Basic, Applied, and Clinical Aspects*. Second. Boston: Academic Press; 2021. p. 69–75.
7. Olesińska M, Saletra A. Quality of life in systemic lupus erythematosus and its measurement. *Reumatologia*. 2018;56(1):45–54.
8. Gokmen K, Barutcu Atas D, Tugcu M, Velioglu A, Hakki Arikian I, Alibaz-Oner F, et al. MO121: The Relationship between Perceived Stress with Anxiety, Depression, Sleep Quality, Insomnia and Drug Adherence in Patients with Systemic Lupus Erythematosus during the COVID-19 Pandemic. *Nephrol Dial Transplant*. 2022 May;37(Supplement\_3):gfac066.024.
9. Chevet B, Figueroa-Parra G, Yang JX, Hulshizer CA, Gunderson TM, Duong SQ, et al. COVID-19 Vaccine Uptake Among Patients With Systemic Lupus Erythematosus in the American Midwest: The Lupus

- Midwest Network (LUMEN). *J Rheumatol*. 2022;49(1):1276–82.
10. Mehta P, Gasparyan AY, Zimba O, Kitas GD. Systemic lupus erythematosus in the light of the COVID-19 pandemic: infection, vaccination, and impact on disease management. *Clin Rheumatol*. 2022;41(9):2893–910.
  11. Yoshida T, Tsuji H, Onishi A, Takase Y, Shirakashi M, Onizawa H, et al. Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus. *Lupus Sci Med*. 2022;9(1):1–7.
  12. Rubbyana U. Hubungan antara Strategi Koping dengan Kualitas Hidup pada Penderita Skizofrenia Remisi Simptom. *J Psikol Klin dan Kesehat Ment*. 2012;1(02):59–66.
  13. Hardianti H. PENGARUH SENSE OF HUMOR TERHADAP KUALITAS HIDUP PADA LANSIA PENSIUNAN DI KOTA MALANG. UNIVERSITAS BRAWIJAYA MALANG; 2014.
  14. McElhone K, Abbott J, Shelmerdine J, Bruce IN, Ahmad Y, Gordon C, et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. *Arthritis Rheum*. 2007 Aug;57(6):972–9.
  15. Yanih I. KUALITAS HIDUP PENDERITA SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) BERDASARKAN LUPUSQOL Quality of Life in Patient with Systemic Lupus Erythematosus (SLE). *Berk Epidemiol*. 2016;1(June):1–12.
  16. WHO. Coronavirus disease (COVID-19): Vaccines. World Health Organization. 2022.
  17. Tamita K, Hasibuan H, Aktalina L, Rifiza C. Hubungan tingkat pengetahuan dengan kepatuhan vaksinasi Covid-19 pada lansia di Kelurahan Babura Kecamatan Medan Sunggal. *J Kedokt Ibnu Nafis*. 2022;11(1):6–13.
  18. BPOM. Vaksin untuk Lansia Dalam Program Vaksinasi COVID-19. BPOM. 2021.
  19. Vaillant AAJ, Goyal A, Varacallo M. Systemic Lupus Erythematosus.

- StatPearls. 2022.
20. Prokunina L, Alarcon-Riquelme M. The genetic basis of systemic lupus erythematosus--knowledge of today and thoughts for tomorrow. *Hum Mol Genet.* 2004 Apr;13 Spec No:R143-8.
  21. Harley ITW, Kaufman KM, Langefeld CD, Harley JB, Kelly JA. Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies. Vol. 10, *Nature reviews. Genetics.* England; 2009. p. 285–90.
  22. Fava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. *J Autoimmun.* 2019 Jan;96:1–13.
  23. Ali A, Sayyed Z, Ameer MA, Arif AW, Kiran F, Iftikhar A, et al. Systemic Lupus Erythematosus: An Overview of the Disease Pathology and Its Management. *Cureus.* 2018 Sep;10(9):e3288.
  24. Tsai HL, Chang JW, Lu JH, Liu CS. Epidemiology and risk factors associated with avascular necrosis in patients with autoimmune diseases: a nationwide study. *Korean J Intern Med.* 2022 Jul;37(4):864–76.
  25. Infodatin. *Situasi Lupus di Indonesia.* Jakarta: PUSDATIN; 2017.
  26. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum.* 1982 Nov;25(11):1271–7.
  27. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Vol. 40, *Arthritis and rheumatism.* United States; 1997. p. 1725.
  28. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum.* 2012 Aug;64(8):2677–86.
  29. Tedeschi SK, Johnson SR, Boumpas D, Daikh D, Dörner T, Jayne D, et al. Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration. *Arthritis Care Res (Hoboken).* 2018 Apr;70(4):571–81.
  30. Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in

- diagnosis and treatment. *Am J Clin Dermatol*. 2009;10(6):365–81.
31. Hejazi EZ, Werth VP. Cutaneous Lupus Erythematosus: An Update on Pathogenesis, Diagnosis and Treatment. *Am J Clin Dermatol*. 2016 Apr;17(2):135–46.
  32. Petri M. Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update. *Arthritis care Res Off J Arthritis Heal Prof Assoc*. 1995 Sep;8(3):137–45.
  33. Bastian HM, Roseman JM, McGwin GJ, Alarcón GS, Friedman AW, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. *Lupus*. 2002;11(3):152–60.
  34. Ainiala H, Hietaharju A, Loukkola J, Peltola J, Korpela M, Metsänoja R, et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. *Arthritis Rheum*. 2001 Oct;45(5):419–23.
  35. De Souza RR, Marcon SS, Teston EF, dos Reis P, de Souza Campos Seguraço R, Silva ES, et al. Factors influencing quality of life in people with systemic lupus erythematosus. *ACTA Paul Enferm*. 2021;34:1–10.
  36. Jolly M, Sequeira W, Block JA, Toloza S, Bertoli A, Blazevic I, et al. Sex Differences in Quality of Life in Patients With Systemic Lupus Erythematosus. *Arthritis Care Res*. 2019;71(12):1647–52.
  37. Rizk A, Gheita TA, Nassef S, Abdallah A. The impact of obesity in systemic lupus erythematosus on disease parameters, quality of life, functional capacity and the risk of atherosclerosis. *Int J Rheum Dis*. 2012;15(3):261–7.
  38. Gomez A, Hani Butrus F, Johansson P, Åkerström E, Soukka S, Emamikia S, et al. Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus. *Rheumatol (United Kingdom)*. 2021;60(3):1260–72.
  39. Sendrasoa FA, Razafimaharo TI, Ramily L, Rakotoarisaona MF, Andrianarison M, Raharolahy O, et al. Quality of life in lupus erythematosus female patients with cutaneous lesions in Antananarivo, Madagascar. *Int J Women's Dermatology*. 2021;7(5):743–6.

40. Kulczycka L, Sysa-Jedrzejowska A, Zalewska-Janowska A, Miniszewska J, Robak E. Quality of life and socioeconomic factors in Polish patients with systemic lupus erythematosus. *J Eur Acad Dermatology Venereol.* 2008;22(10):1218–26.
41. Almehed K, Carlsten H, Forsblad-D'Elia H. Health-related quality of life in systemic lupus erythematosus and its association with disease and work disability. *Scand J Rheumatol.* 2010;39(1):58–62.
42. Kernder A, Elefante E, Chehab G, Tani C, Mosca M, Schneider M. The patient's perspective: Are quality of life and disease burden a possible treatment target in systemic lupus erythematosus? *Rheumatol (United Kingdom).* 2020;59:V63–8.
43. Holloway L, Humphrey L, Heron L, Pilling C, Kitchen H, Højbjerg L, et al. Patient-reported outcome measures for systemic lupus erythematosus clinical trials: A review of content validity, face validity and psychometric performance. *Health Qual Life Outcomes.* 2014;12(1).
44. Brailovski E, Vinet E, Pineau CA, Lee J, Lukusa L, Kalache F, et al. Marital status and age of systemic lupus erythematosus diagnosis: The potential for differences related to sex and gender. *Lupus Sci Med.* 2019;6(1):1–4.
45. Mazzoni D, Cicognani E, Prati G. Health-related quality of life in systemic lupus erythematosus : a longitudinal study on the impact of problematic support and self-efficacy. 2016;1–7.
46. Catiuscia T, Lima K, Rodrigues R, Tosta B. The effect of therapies on the quality of life of patients with systemic lupus erythematosus : a meta-analysis of randomized trials. 2019;4–11.
47. Fanouriakis A, Tziolos N, Bertias G, Boumpas DT. Update on the diagnosis and management of systemic lupus erythematosus. 2020;1–12.
48. Mason A, Anver H, Lwin M, Holroyd C, Faust SN, Edwards CJ. Lupus, vaccinations and COVID-19: What we know now. *Lupus.* 2021 Sep;30(10):1541–52.
49. Erik L, Christian B, Bøgh J, Signe A, Vils R, Mistegaard CE, et al. Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients

- with systemic lupus erythematosus and rheumatoid arthritis. *Rheumatol Int.* 2021;41(11):1925–31.
50. Tjan B, Kambayana G, Kurniari PK. Gambaran profil systemic lupus erythematosus (SLE) dan lupus nefritis di Rumah Sakit Umum Pusat Sanglah. *J Penyakit Dalam Udayana.* 2022;6(2):31–5.
  51. Kirwiastiny R, Alfarisi R, Al-Aziz Marjaen A. Hubungan Derajat Aktivitas Penyakit Lupus Eritematosus Sistemik Berdasarkan Skor Mex-Sledai Dengan Kejadian Anemia Pada Penderita Lupus Eritematosus Sistemik Di Komunitas Odapus Lampung Abstract : Relationship of Systemic Lupus Erythematosus Activities Ba. 2021;3.
  52. Nadhiroh, F. *Lupus: penyakit seribu wajah dominan menyerang wanita.* 2007.
  53. Nancy & Ikawati. Z, 2012. Evaluasi Pengobatan Systemic Lupus Erythematosus (LES) pada Pasien LES Dewasa. *Journal Of Management and Pharmacy Practice.* 2 (3) : 127-194.
  54. Wallace, D.J. *The Lupus Book.* 4th edition ed. Los Angeles: Oxford University; 2009.
  55. Aryaningrum E, Salim EM, Apriansyah MA, Bahar E, Kusnadi Y. Hubungan Antara Kadar Interleukin 10 Serum dengan Tingkat Depresi Penderita Lupus Eritematosus Sistemik di RSUP Dr. Mohammad Hoesin Palembang. *Sriwij J Med.* 2021;4(3):164–74.
  56. Zhu, L., Zhang, T., Pan, H., Pei-Li, X., Ye, D. BMI, disease activity, and health-related qualityof-life in systemic lupus erythematosus. *Clin Rheumatol.* 2010;29:1413–1417.
  57. Sterling, K.L., Gallop, K., Swinburn,P.,, Flood,E., French,A., Al Sawah,S., Likuni,N., Naegeli,A.N, dan Nixon,A. Patient-reported fatigue and its impact on patient with systemic lupus erythematosus. *Lupus.* 2014;23: 124–132.
  58. Barnado, A., Wheless, L., Meyer, A. K., Gilkeson, G.S. & Kamen, DL. Quality of Life in Patient with Systemic Lupus Erythematosus compared with related controls within a unique African American population. *Lupus.* 2012; 21:563–569.

59. Sari I. Kulit hidup pada orang dengan Lupus di yayasan Lupus Bali Tahun 2019. *J Ris Kesehat Nas*. 2020;5(1):88–100.
60. Sari NPWP. Faktor Pencetus Gejala dan Perilaku Pencegahan Systemic Lupus Erythematosus (Precipitating Factors and Preventive Behavior towards the Exposures of Systemic Lupus Erythematosus). *J Ners*. 2016;11(2):213–9.
61. Sheba S, Mutyara K, Rinawan F. Kepatuhan Minum Obat Pada Pasien Lupus Eritematosus Sistemik Drug Adherence Drug in Systemic Lupus Erythematosus Patients in Dr . Hasan Sadikin General Hospital Bandung. *Maj Kedokt Bandung*. 2018;50(369):21–8.
62. Esfandiari F, Rusmini H, Santoso NR. Hubungan Penerimaan Diri Dengan Kualitas Hidup Pada Pasien Lupus Eritematosus Sistemik (Les) Di Komunitas Odapus Provinsi Lampung (Kol)Tahun 2018. *J Ilmu Kedokt dan Kesehat*. 2019;5(3).
63. Khatri G, Priya, Shaikh S, Aashish, Rai A, Cheema HA, et al. Systematic lupus erythematosus patients following COVID-19 vaccination: Its flares up and precautions. *Ann Med Surg [Internet]*. 2022;80(June):104282. Available from: <https://doi.org/10.1016/j.amsu.2022.104282>
64. Montero-López E, Peralta-Ramírez MI, Ortego-Centeno N, Callejas-Rubio JL, Ríos-Fernández R, Santos-Ruiz A. Psychological and quality of life effects of vaccination against COVID-19 in patients with systemic autoimmune diseases. *Lupus*. 2022;31(14):1808–15.
65. Koltai J, Raifman J, Bor J, McKee M and Stuckler D. COVID-19 vaccination and mental health: a difference-indifference analysis of the understanding America study. *Am J Prev Med* 2021; 000(000): 1–9.
66. Montero-López E, Santos-Ruiz A, Gonzalez R, et al. Analyses of hair and salivary cortisol for evaluating hypothalamic–pituitary– adrenal axis activation in patients with autoimmune disease. *Stress* 2017; 20: 541–548.
67. Furer V, Rondaan C, Agmon-Levin N, et al. Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases. *RMD Open* 2021; 7: e001594.